Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634292 | 0.90 | TTR (0.56) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL26634041 | 0.82 | ESR1 (0.63) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL31428564 | 0.82 | ESR1 (0.63) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL30634275 | 0.77 | TTR (0.59) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL26791145 | 0.77 | TTR (0.59) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL11217091 | 0.77 | TTR (0.71) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL11217092 | 0.77 | TTR (0.71) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL2056140 | 0.76 | HSD17B10 (0.50) | ESR1NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL6953319 | 0.76 | TTR (0.58) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL6953315 | 0.76 | TTR (0.58) | TTRDPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270187-A1 | MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | THE SCRIPPS RESEARCH INSTITUTE | 2025-08-28 | — | — | US | disclosed |
| WO-2023212565-A2 | MOLECULAR EDITING OF MULTIPLE C-H BONDS BY LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212565-A2 | MOLECULAR EDITING OF MULTIPLE C-H BONDS BY LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-7935827-B2 | Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters | BAYER SCHERING PHARMA AG (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935827-B2 | Optically active, heteroaromatic β-hydroxy esters and processes for their preparation from β-keto esters and processes for the preparation of these β-keto esters | BAYER SCHERING PHARMA AG (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20100248313-A1 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS | BAYER SCHERING PHARMA AG (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100248313-A1 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS | BAYER SCHERING PHARMA AG (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7626035-B2 | Ethyl 2-(benzothiazol-2-yl),2-oxo-acetate; useful in the synthesis of epothilonederivatives; antitumor,-carcinogenic agents; high chemical purity, optical purity,in very good yields and allows an industrial-scale production | BAYER SCHERING PHARMA AG (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7626035-B2 | Ethyl 2-(benzothiazol-2-yl),2-oxo-acetate; useful in the synthesis of epothilonederivatives; antitumor,-carcinogenic agents; high chemical purity, optical purity,in very good yields and allows an industrial-scale production | BAYER SCHERING PHARMA AG (DE) | 2009-12-01 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | TTR 531/4885DPP4 2947/4885CA12 4227/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | TTR 531/4885DPP4 2947/4885CA12 4227/4885 |
| US-20100248313-A1 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS | CYP8B1, HSD17B7, CYP51A1 | TTR 2772/4885DPP4 2727/4885CA12 4083/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | TTR 661/4885DPP4 2679/4885CA12 3696/4885 |
| US-20250270187-A1 | MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | CYCS, CYC1, CDA | TTR 824/4885DPP4 1615/4885CA12 3560/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | TTR 531/4885DPP4 2947/4885CA12 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.